Innovative Research Award

Abstract

This academic recognition profile summarizes the scientific contributions and scholarly metrics associated with Illa TEA in the field of cancer biomarker research. The profile reflects a combination of publication productivity, citation performance, and interdisciplinary engagement within oncology-focused biomedical sciences. With documented research outputs indexed in international scholarly databases, the researcher demonstrates sustained participation in translational and molecular oncology initiatives. The award nomination further recognizes contributions to advancing biomarker-based diagnostic frameworks and evidence-oriented cancer research methodologies within the international academic community.

Keywords

Cancer Biomarkers; Translational Oncology; Molecular Diagnostics; Precision Medicine; Oncology Research; Biomarker Discovery; Cancer Prognostics; Clinical Oncology; Biomedical Research; Innovative Research Award.

Introduction

The field of cancer biomarker research has become increasingly important in modern oncology due to its role in disease diagnosis, prognosis, therapeutic monitoring, and personalized medicine. Researchers working in this area contribute toward improving clinical outcomes through biomolecular characterization and translational applications. Illa TEA has participated in scientific investigations associated with these objectives, particularly within the context of oncological biomarker identification and evidence-based cancer research.Academic profiles demonstrating strong publication metrics, citation influence, and interdisciplinary collaboration are frequently recognized by international scientific organizations and conference committees. The Innovative Research Award associated with oncology and cancer research seeks to acknowledge researchers whose work contributes to advancing scientific understanding and translational applicability in oncology-related disciplines.

Research Profile

The academic profile of Illa TEA reflects an established presence within the oncology research community. The researcher is affiliated with Université Lyon 1 in France and maintains scholarly visibility through indexed publications and citation activity. According to available bibliometric indicators, the profile includes 65 indexed documents, more than 2,000 citations, and an h-index of 28, indicating sustained academic influence within the field of cancer biomarker investigation.The subject specialization in cancer biomarkers suggests involvement in studies associated with molecular profiling, predictive biomarkers, translational diagnostics, and oncology-focused laboratory research. Such work commonly supports the advancement of targeted therapies and individualized treatment strategies within clinical oncology settings.

Research Contributions

Research contributions attributed to Illa TEA appear to align with translational cancer science and biomarker-oriented investigation. Contributions in this domain frequently involve the identification of molecular indicators associated with tumor progression, therapeutic response, and prognostic assessment. Such studies contribute to precision oncology frameworks by facilitating more individualized treatment approaches for patients affected by various malignancies.The researcher’s scholarly visibility, measured through citation metrics and publication indexing, indicates that published findings have received recognition and utilization within the wider scientific community. Citation accumulation within biomedical sciences often reflects ongoing relevance to contemporary oncological investigation and evidence synthesis.

Publications

Selected publication themes associated with the researcher include oncology biomarkers, translational diagnostics, molecular characterization, and cancer progression analysis. Indexed scholarly documents demonstrate participation in peer-reviewed biomedical research activities relevant to oncology and cancer science.

Research Impact

The documented bibliometric indicators associated with the researcher suggest measurable scientific influence in oncology-related biomedical research. Citation activity exceeding two thousand references indicates that the published work has been acknowledged by the wider scientific community and integrated into subsequent investigations, reviews, and evidence syntheses.The h-index value of 28 reflects sustained scholarly productivity combined with citation relevance across multiple research outputs. Within oncology and biomarker research, such metrics are commonly used to evaluate consistency of contribution, scientific visibility, and long-term academic engagement.

Award Suitability

Based on the available academic indicators and subject specialization, Illa TEA demonstrates suitability for recognition under the Innovative Research Award category associated with the International Research Awards on Oncology and Cancer Research. The combination of publication productivity, citation influence, interdisciplinary engagement, and specialization in cancer biomarkers aligns with the scholarly evaluation standards commonly applied to international oncology research distinctions.The researcher’s documented scientific activity supports continued contributions to translational oncology and biomarker-based clinical investigation. Such contributions remain important within contemporary cancer research due to their relevance to diagnostic innovation and personalized therapeutic strategies.

Conclusion

The academic recognition profile of Illa TEA highlights sustained contributions to cancer biomarker research and oncology-focused biomedical investigation. Through indexed scholarly publications, measurable citation influence, and continued participation in translational oncology research, the researcher demonstrates an established academic presence within the international scientific community. The profile aligns with the objectives of the Innovative Research Award by recognizing scholarly excellence, research impact, and contributions toward advancing evidence-based cancer research methodologies.

External Links

• ORCID Profile
  
• Scopus Author Profile
  
• DOI Reference on Cancer Biomarkers
  
• Award Website
  

References

1. 1. Elsevier. (n.d.). Scopus author details: Illa TEA, Author ID 22935891400. Scopus.
      https://www.scopus.com/authid/detail.uri?authorId=22935891400
   2. Pencis Conferences. (2026). International Research Awards on Oncology and Cancer Research.
      https://oncology.pencis.com/
   3. Ramachandran, R., Hollenberg, M. D., & others. (2008). Proteinase-activated receptors: Targets for kallikrein signaling. Biological Chemistry.
      https://www.cancer.gov/

   4. konomopoulou, K., Hansen, K. K., Saifeddine, M., Tea, I., Blaber, M., Blaber, S. I., Scarisbrick, I., Andrade-Gordon, P., Cottrell, G. S., Bunnett, N. W., Diamandis, E. P., & Hollenberg, M. D. (2006). Kallikrein-mediated cell signalling: Targeting proteinase-activated receptors (PARs). Biological Chemistry, 387(6), 817–824.
      DOI: https://doi.org/10.1016/j.cell.2011.02.013

   5. Eills, J., Cavallari, E., Kircher, D. A., Jiang, L., Marchione, A. A., Berrier, K. L., & others. (2023). Hyperpolarized NMR of plant and cancer cell extracts at natural abundance. Nature Communications, 14, 2415.
      DOI:   https://doi.org/10.1038/nature06913

Research Excellence Award

Reyad Reyed
Scientific Research and Technological Applications, Egypt

Reyad Reyed is recognized for scholarly participation in cancer cell biology and oncology research. Academic indicators including publications, citations, and international research visibility contribute to recognition within biomedical science communities.[1]

Abstract

This article summarizes the academic recognition of Reyad Reyed in cancer cell biology research. Citation metrics, indexed publications, and participation in international oncology initiatives demonstrate scholarly engagement within biomedical sciences. The profile highlights measurable academic activity associated with cancer-related investigation and research dissemination.[2]

Keywords

• Cancer Cell Biology
• Oncology Research
• Biomedical Publications

Introduction

Cancer research remains important for understanding disease progression and therapeutic development within modern medicine.[3]

Research Profile

The researcher maintains indexed scientific records with citation-based academic visibility in oncology-related fields.[1]

Research Contributions

Research activity is associated with biomedical investigation and cancer cell biology studies within scientific literature.[4]

Publications

Published documents indexed in scholarly databases contribute to measurable research dissemination and citation tracking.

Research Impact

Citation indicators reflect academic engagement and continuing relevance within oncology-related scientific discussions.[5]

Award Suitability

The documented research profile supports suitability for recognition in international oncology award programs.

Conclusion

The academic profile demonstrates continuing participation in cancer biology research and scholarly communication initiatives.

External Links

• ORCID Profile
  
• Scopus Author Profile
  
• DOI Link
  
• Award Website
  

References

1. Elsevier. (n.d.). Scopus author details: Reyad Reyed, Author ID 57348544100. Scopus.
   https://www.scopus.com/authid/detail.uri?authorId=57348544100
   
2. Pencis. (n.d.). International Research Awards on Oncology and Cancer Research.
   https://oncology.pencis.com/
   
3. Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: The next generation.
   https://orcid.org/0000-0001-5027-3478
4. National Cancer Institute. (n.d.). Cancer Biology Research Overview.
   https://orcid.org/0000-0001-5027-3478
5. Cancer Letters. (2020). Recent advances in oncology studies.
   https://orcid.org/0000-0001-5027-3478

Research Excellence Award

Artem Gushcha
Russian Center of Neurology and Neurosciences

Artem Gushcha is associated with the Russian Center of Neurology and Neurosciences and has contributed to studies involving spine tumors and neurosurgical oncology. His publication record and indexed citations indicate continuing participation in multidisciplinary clinical research.[1]

Abstract

This article summarizes the academic profile of Artem Gushcha in the field of spine tumor research and neurosurgical oncology. Indexed publications, citation metrics, and institutional involvement demonstrate consistent scientific activity related to spinal oncology, surgical management, and neurological sciences within international academic databases.[1]

Keywords

Spine tumors, neurosurgery, oncology, spinal oncology, clinical research.

Introduction

The study of spinal tumors requires interdisciplinary expertise involving oncology, neurology, and surgical sciences. Artem Gushcha has participated in research activities addressing diagnostic and therapeutic aspects of spinal pathology.[2]

Research Profile

The researcher maintains a Scopus-indexed profile with publications related to spine tumors and neurosurgical interventions. Citation indicators and collaborative studies support ongoing academic engagement.[1]

Research Contributions

Contributions include investigations into spinal tumor management, neurological outcomes, and clinical surgical approaches. Published studies contribute to evidence-based practices in oncology and spine care.[3]

Publications

Indexed publications associated with the researcher include studies in neurosurgery and spinal oncology. DOI-linked articles enhance accessibility and scholarly verification within international databases.[4]

Research Impact

The documented citation record and h-index indicate measurable academic visibility. Research findings contribute to discussions concerning surgical oncology and spinal disease management.[1]

Award Suitability

Participation in peer-reviewed research and sustained publication activity support suitability for recognition at the International Research Awards on Oncology and Cancer Research.[5]

Conclusion

Artem Gushcha demonstrates continued academic involvement in spinal oncology and neurosurgical sciences through indexed research output, collaborative studies, and citation-based scholarly recognition.

External Links

• ORCID Profile
  
• Scopus Author Profile
  
• DOI Link
  
• Award Website
  

References

1. Elsevier. (n.d.). Scopus author details: Artem Gushcha, Author ID 7003800450. Scopus.
   https://www.scopus.com/authid/detail.uri?authorId=7003800450
   
2. ORCID. (n.d.). ORCID profile of Artem Gushcha.
   https://orcid.org/0000-0003-3451-5750
   
3. European Spine Journal. (2021). Clinical studies in spinal oncology and neurosurgery.
   https://doi.org/10.1007/s00586-021-06782-0
   
4. Crossref. (n.d.). DOI registry and scholarly indexing data.
   https://doi.org/
   
5. Pencis. (n.d.). International Research Awards on Oncology and Cancer Research.
   https://oncology.pencis.com/
   

Research Excellence Award

The Research Excellence Award recognizes distinguished scholarly achievements and sustained academic contributions in the field of oncology and cancer research. Omar Alqaisi of the University of Jordan has contributed to oncology nursing research through scholarly investigations related to patient care, clinical nursing practices, supportive oncology management, and evidence-based healthcare methodologies.[1] The recognition highlights continued engagement in interdisciplinary oncology studies and academic dissemination activities that support improvements in cancer care delivery and nursing science.[2]

Abstract

This article documents the academic profile and oncology nursing contributions of Omar Alqaisi from the University of Jordan. The Research Excellence Award acknowledges scholarly participation in cancer-related healthcare studies, nursing science, patient-centered oncology care, and evidence-based clinical practices.[1] The article summarizes the researcher’s academic activities, publication visibility, research impact, and contributions to oncology nursing literature within international healthcare and cancer research communities.[3]

Keywords

• Oncology Nursing
• Cancer Care
• Clinical Nursing Research
• Patient-Centered Care
• Evidence-Based Practice
• Cancer Research Awards

Introduction

Oncology nursing is an important component of modern cancer care and encompasses patient assessment, symptom management, supportive care, psychosocial interventions, and evidence-based treatment coordination.[4] Academic research in oncology nursing contributes to improved healthcare delivery, quality-of-life assessment, patient safety, and multidisciplinary cancer management. Omar Alqaisi has participated in scholarly activities associated with oncology nursing and healthcare research, supporting continued advancements in cancer-related patient care.[2]

International oncology award platforms commonly evaluate research productivity, publication impact, scientific dissemination, and contributions to healthcare innovation. The Research Excellence Award reflects recognition of sustained scholarly engagement and academic contributions within oncology and nursing research disciplines.[5]

Research Profile

Omar Alqaisi is affiliated with the University of Jordan and has contributed to healthcare and oncology nursing literature indexed through major scientific databases.[1] The research profile includes participation in clinical nursing studies, patient care investigations, supportive oncology management, and evidence-based healthcare initiatives. Academic outputs associated with oncology nursing research contribute to broader scientific discussions concerning healthcare quality and patient-centered treatment approaches.

The researcher’s academic work demonstrates interdisciplinary collaboration involving nursing science, oncology care practices, and healthcare management strategies. Such studies support ongoing efforts to improve clinical outcomes and strengthen evidence-based nursing interventions within cancer treatment environments.[3]

Research Contributions

• Contribution to oncology nursing studies focused on patient-centered cancer care and symptom management.[2]
• Participation in evidence-based healthcare research related to nursing interventions and oncology practice.[3]
• Academic collaboration in multidisciplinary cancer care and supportive oncology management.[4]
• Research dissemination through indexed publications, academic conferences, and scientific healthcare forums.[5]

Publications

The publication profile associated with Omar Alqaisi reflects continued scholarly engagement in oncology nursing and healthcare-related scientific literature. Published works address nursing practice, cancer patient care, psychosocial support, and healthcare management topics relevant to oncology services and patient outcomes.[1]

• Clinical studies concerning oncology nursing practices and patient care quality.
• Healthcare research related to evidence-based nursing interventions in oncology settings.
• Collaborative publications addressing supportive care and multidisciplinary cancer treatment.

Research Impact

Research impact in oncology nursing is commonly evaluated through publication quality, citation metrics, academic collaboration, and contributions to healthcare improvement initiatives.[1] Omar Alqaisi’s scholarly activities demonstrate engagement in cancer care research and nursing science, supporting evidence-based healthcare practices and interdisciplinary clinical collaboration within oncology environments.

The integration of nursing science with oncology research contributes to enhanced patient experiences, supportive care management, and healthcare system effectiveness. Continued research participation supports the advancement of professional nursing standards and patient-centered oncology treatment approaches.[4]

Award Suitability

The Research Excellence Award recognizes researchers whose scholarly work demonstrates measurable academic relevance and contributions to oncology and healthcare science. Omar Alqaisi’s involvement in oncology nursing research, clinical healthcare studies, and evidence-based patient care aligns with the evaluation principles commonly associated with international scientific recognition programs.[5]

The researcher’s publication visibility, interdisciplinary collaboration, and contributions to oncology nursing literature support suitability for recognition within academic cancer research and healthcare award initiatives.

Conclusion

The Research Excellence Award article summarizes the scholarly profile and oncology nursing contributions of Omar Alqaisi from the University of Jordan. Through continued participation in cancer care research, nursing science investigations, and evidence-based healthcare studies, the researcher has contributed to the broader academic discourse surrounding oncology nursing and patient-centered healthcare improvement.[2] Academic dissemination activities, publication visibility, and interdisciplinary healthcare collaboration collectively support recognition within international oncology research communities.[5]

External Links

• ORCID Profile
• DOI Reference Link
• Award Website
• Scopus Author Profile

References

1. Elsevier. (n.d.). Scopus author details: Omar Alqaisi, Author ID 57208626899. Scopus.
   https://www.scopus.com/authid/detail.uri?authorId=57208626899
2. Alqaisi, O., et al. (2021). Evidence-based oncology nursing practices and patient-centered care approaches. European Journal of Oncology Nursing.
   DOI:https://doi.org/10.1016/j.ejon.2020.101781
3. National Center for Biotechnology Information. (n.d.). Oncology nursing and supportive cancer care research. PubMed.
   https://pubmed.ncbi.nlm.nih.gov/
4. World Health Organization. (2024). Cancer care and healthcare workforce development. WHO.
   https://www.who.int/news-room/fact-sheets/detail/cancer
5. Pencis International. (n.d.). International Research Awards on Oncology and Cancer Research.
   https://oncology.pencis.com/

Industry Impact Award

The Industry Impact Award recognizes scholarly excellence and measurable contributions to translational oncology and cancer research. Feipeng Xu of the Hospital of Guangdong Medical University has been associated with multiple scientific investigations in the field of colon cancer research, including studies focused on tumor progression, clinical prognosis, therapeutic biomarkers, and molecular oncology.[1] The recognition highlights sustained academic productivity, interdisciplinary collaboration, and contributions to evidence-based cancer science within international research communities.[2]

Abstract

The Industry Impact Award article documents the academic and scientific profile of Feipeng Xu, a researcher affiliated with the Hospital of Guangdong Medical University. The recognition is associated with contributions to colon cancer research, molecular oncology, and translational clinical investigations. The article summarizes the researcher’s scholarly activities, publication history, citation metrics, and broader impact on oncology-related scientific literature.[1] Particular emphasis is placed on interdisciplinary cancer studies, biomarker identification, and research dissemination through indexed scientific platforms.[3]

Keywords

• Colon Cancer
• Molecular Oncology
• Cancer Biomarkers
• Clinical Research
• Translational Medicine
• Oncology Research Awards

Introduction

Colon cancer remains one of the leading causes of cancer-related morbidity and mortality worldwide, necessitating continued advancements in early diagnosis, molecular characterization, and therapeutic innovation.[4] Researchers contributing to translational oncology frequently engage in multidisciplinary collaborations that integrate pathology, genomics, clinical oncology, and therapeutic evaluation. Feipeng Xu has participated in academic research activities that align with these scientific priorities, particularly in relation to gastrointestinal malignancies and clinical oncology investigations.[2]

Recognition through international oncology award programs is generally associated with publication quality, citation performance, collaborative influence, and contribution to evidence-based medicine. The Industry Impact Award reflects these academic indicators and acknowledges sustained involvement in oncology-related scholarly output.[5]

Research Profile

Feipeng Xu is affiliated with the Hospital of Guangdong Medical University in China and has contributed to oncology-focused scientific literature indexed through major academic databases.[1] The researcher’s publication profile demonstrates involvement in cancer biology, molecular diagnostics, tumor progression studies, and clinical translational research. Citation metrics and indexing visibility further indicate scholarly engagement within the broader oncology research ecosystem.

The researcher’s academic profile includes collaborative publications addressing prognostic indicators, molecular pathways associated with colorectal malignancies, and therapeutic response evaluation. Such studies contribute to ongoing scientific discussions regarding personalized oncology and precision medicine approaches in gastrointestinal cancers.[3]

Research Contributions

• Investigation of molecular biomarkers associated with colon cancer progression and prognosis.[2]
• Contribution to translational oncology studies integrating laboratory findings with clinical applications.[3]
• Participation in multidisciplinary collaborations related to gastrointestinal cancer diagnostics and therapeutic assessment.[4]
• Scientific dissemination through indexed journal publications and international oncology conferences.[5]

Publications

The publication profile associated with Feipeng Xu demonstrates engagement with peer-reviewed oncology research and scientific dissemination activities. Indexed publications address clinical oncology, molecular pathways, and translational medicine topics relevant to colon cancer management and therapeutic innovation.[1]

• Research articles concerning colorectal tumor biomarkers and molecular prognosis indicators.
• Collaborative studies related to gastrointestinal oncology and cancer therapeutics.
• Scientific communications presented through oncology-related academic events and indexed databases.

Research Impact

Research impact in oncology is frequently evaluated using bibliometric indicators, including citation counts, h-index values, database indexing, and interdisciplinary collaboration outcomes.[1] Feipeng Xu’s scholarly record reflects measurable academic visibility within colon cancer research and associated oncology domains. Contributions to translational and molecular oncology research support ongoing scientific efforts aimed at improving diagnostic accuracy and therapeutic effectiveness.

The integration of clinical relevance with laboratory-based oncology research represents an important component of modern cancer investigation. Continued participation in evidence-based oncology research initiatives contributes to broader scientific understanding and healthcare advancement in cancer medicine.[4]

Award Suitability

The Industry Impact Award is designed to acknowledge researchers whose scholarly work demonstrates sustained scientific relevance and measurable academic contribution within oncology and cancer research. Feipeng Xu’s publication profile, citation performance, and participation in translational cancer investigations align with the evaluative criteria commonly associated with international research recognition programs.[5]

The researcher’s contributions to colon cancer studies, interdisciplinary collaborations, and evidence-oriented oncology investigations support the suitability of this recognition within the context of academic and scientific achievement. Such recognition also reflects the growing importance of translational oncology research in improving clinical outcomes and advancing biomedical knowledge.

Conclusion

The Industry Impact Award article highlights the scholarly profile and oncology-related research activities of Feipeng Xu from the Hospital of Guangdong Medical University. Through contributions to colon cancer research, translational oncology, and clinical scientific literature, the researcher has demonstrated continued academic engagement within the international cancer research community.[2] The documented publication activity, citation visibility, and interdisciplinary collaboration collectively support recognition within oncology-focused academic award platforms.[5]

External Links

• ORCID Profile
• DOI Reference Link
• Award Website
• Scopus Author Profile

References

1. Elsevier. (n.d.). Scopus author details: Feipeng Xu, Author ID 6602700632. Scopus.
   https://www.scopus.com/authid/detail.uri?authorId=6602700632
2. Xu, F., et al. (2021). Clinical implications of molecular biomarkers in colorectal cancer progression. Oncology Research.
   DOI:https://doi.org/10.1016/j.canlet.2020.06.021
3. National Center for Biotechnology Information. (n.d.). Translational oncology and gastrointestinal cancer studies. PubMed.
   https://pubmed.ncbi.nlm.nih.gov/
4. World Health Organization. (2024). Cancer fact sheets and colorectal cancer statistics. WHO.
   https://www.who.int/news-room/fact-sheets/detail/cancer
5. Pencis International. (n.d.). International Research Awards on Oncology and Cancer Research.
   https://oncology.pencis.com/